SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends
16 references·0 citing·42 second hop
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends (2017)Risk-Sharing Agreements in the EU: A Syst…Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review (2015)Disinvestment and Value-Based…Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden (2014)Dealing with uncertainty and …Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries (2013)Reconciling uncertainty of co…Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force (2013)Performance-Based Risk-Sharin…Managed entry agreements for pharmaceuticals: the European experience (2013)Managed entry agreements for …What principles should govern the use of managed entry agreements? (2011)What principles should govern…Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement (2011)Risk-Sharing Arrangements Tha…Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)Risk sharing arrangements for…Canʼt Get No Satisfaction? Will Pay for Performance Help? (2010)Canʼt Get No Satisfaction? Wi…The Use of Qualitative Content Analysis in Case Study Research (2008)The Use of Qualitative Conten…Qualitative Content Analysis (2008)Qualitative Content AnalysisPharmaceutical Risk-Sharing Agreements (2008)Pharmaceutical Risk-Sharing A…OFT, VBP: QED? (2007)OFT, VBP: QED?Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle (2004)Inclusion of cost effectivene…Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosis (2003)Modelling the cost effectiven…Research Design: Qualitative, Quantitative, and Mixed Methods Approaches (1994)Research Design: Qualitative,…Comparative Effectiveness Research: A Report From the Institute of Medicine (2009)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers (2010)Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications (2014)The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications (2017)Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985)Time Preference (1996)Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis (2007)Access with Evidence Development Schemes (2010)Cost-effectiveness of disease-modifying therapy for multiple sclerosis (2011)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Health Economic Guidelines—Similarities, Differences and Some Implications (2001)Theory versuspractice: a review of ?willingness-to-pay? in health and health care (2001)Measuring Preferences for Cost-Utility Analysis (2007)Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions (2012)Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC—Does the Presence of an Explicit Threshold Affect the ICER Proposed? (2018)Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions (2009)Health systems in transition. (2010)Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study (2015)How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries (2017)THE DISCOVERY OF GROUNDED THEORY: STRATEGIES FOR QUALITATIVE RESEARCH. By Barney G. Glaser and Anselm L. Strauss. Chicago: Aldine Publishing Company, 1967. 271 pp. $6.75 (1968)Content Analysis: An Introduction to its Methodology. (1984)Basics of Qualitative Research: Grounded Theory Procedures and Techniques. (1992)Three Approaches to Qualitative Content Analysis (2005)Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study (2013)Building dynamic capabilities for digital transformation: An ongoing process of strategic renewal (2018)Case Study Research: Design and Methods (1984)Handbook of Qualitative Research (1994)Sustainability reports as simulacra? A counter-account of A and A+ GRI reports (2013)Giving too much social support: social overload on social networking sites (2014)A dynamic perspective on the resilience of firms: A systematic literature review and a framework for future research (2019)International Journal of Technology Assessment in Health Care (review) (1987)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report (2005)Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force (2020)Using Mixed-Methods Sequential Explanatory Design: From Theory to Practice (2005)Case study research: design and methods (2011)What is Qualitative in Qualitative Research (2019)Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks (2017)Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future (2017)Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy (2023)
this work references cited by second hop

References

  • 1994Research Design: Qualitative, Quantitative, and Mixed Methods Approaches35,275 cited
  • 2008Qualitative Content Analysis6,565 cited
  • 2008The Use of Qualitative Content Analysis in Case Study Research942 cited
  • 2013Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force319 cited
  • 2010Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers255 cited
  • 2004Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle194 cited
  • 2013Managed entry agreements for pharmaceuticals: the European experience167 cited
  • 2014Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden156 cited
  • 2011What principles should govern the use of managed entry agreements?155 cited
  • 2003Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosis142 cited
  • 2010Canʼt Get No Satisfaction? Will Pay for Performance Help?124 cited
  • 2013Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries122 cited
  • 2007

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

OFT, VBP: QED?
114 cited
  • 2011Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement109 cited
  • 2015Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review92 cited
  • 2008Pharmaceutical Risk-Sharing Agreements90 cited
  • Cited by

    No citing works inside the corpus for this window.